PDSB
PDS Biotechnology Corporation
There isn't enough reported data to score PDSB yet.
PDSB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PDSB's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
PDSB PE Valuation
PDSB has no meaningful PE right now: it lost money over the past year.
PDSB Forward outlook
There aren't enough analyst estimates for PDSB to show an outlook.
PDSB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.63 | +$0.29 |
| Q1 2026 | -$0.66 | +$0.28 |
| Q4 2025 | -$0.74 | +$0.29 |
| Q3 2025 | -$0.82 | +$0.35 |
| Q2 2025 | -$0.92 | +$0.31 |
| Q1 2025 | -$0.94 | +$0.43 |
| Q4 2024 | -$1.03 | +$0.36 |
| Q3 2024 | -$1.17 | +$0.52 |
PDSB is still losing money, but far less than before: $0.63 per share over the past year, against $3.30 at its worst in early 2020.
PDSB Quarterly Revenue
PDSB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.4M | +$4.7M |
| Q4 2025 | -$3.7M | +$4.5M |
| Q3 2025 | -$5.9M | +$2.1M |
| Q1 2025 | -$9M | +$905.9K |
| Q4 2024 | -$8.2M | +$222.7K |
| Q3 2024 | -$8M | -$823.8K |
| Q1 2024 | -$9.9M | +$3.3M |
| Q4 2023 | -$8.5M | -$928.2K |
PDSB has burned cash in almost every quarter: −$17M over the past year, against −$35M the year before.
PDSB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +163K shares |
| 1 year | +21% | +9.8M shares |
| 3 years | +81% | +24.9M shares |
| 5 years | +140% | +32.5M shares |
| Available history | +961% | +50.4M shares |
PDSB has 56M diluted shares, up 21% from a year ago.
PDSB Net Leverage
PDSB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PDSB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.1 | Neutral |
| Stochastic | 64.0 | Neutral |
PDSB's weekly RSI is 52 (neutral) and its Stochastic is 64 (neutral).
PDSB PE vs Healthcare Sector
PDSB has no meaningful PE right now: it lost money over the past year.
PDSB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.10 | 11% below |
| 20 week MA | $0.77 | 27% above |
| 50 week MA | $0.85 | 15% above |
| 100 week MA | $1.05 | 6.7% below |
| 200 week MA | $2.96 | 67% below |
PDSB's trend is mixed: it's above two of its five weekly moving averages, and 67% below its 200-week average.
PDSB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.97 | $2.31 | -22% |
| 2021 | $2.31 | $9.00 | +290% |
| 2022 | $9.00 | $9.77 | +8.6% |
| 2023 | $9.77 | $4.97 | -49% |
| 2024 | $4.97 | $1.71 | -66% |
| 2025 | $1.71 | $0.90 | -47% |
| 2026 YTD | $0.90 | $0.98 | +8.9% |
PDSB has finished three years in a row lower, and it's up 8.9% so far in 2026.